Business identity and shareholding
Predilife business identity and shareholding
A few words about Predilife
Editorial by Stéphane Ragusa,
“Since its creation in 2004, Predilife has been at the heart of predictive medicine, offering targeted and effective prevention through innovative devices based on artificial intelligence and Big Data. The company has forged strategic partnerships with the largest breast cancer databases in the world, allowing us to create a predictive model for this disease, the MammoRisk® solution, which has gained recognition in Europe.
Since 2021, Predilife has expanded its predictive range to include the most common types of cancer: prostate cancer, melanoma, colorectal cancer, lung cancer and cardiovascular disease, to consolidate its position as a pioneer of predictive medicine.
This health check-up, intended for businesses, allows managers, occupational health and HR departments to prioritise employee health. Our new-generation predictive health check-ups also allow business to develop their commitment to employee health in line with the French law of 2 August 2021.”
Chief Executive Officer
Listed on: Euronext Growth Paris
ISIN / Mnemo code: FR0010169920 / ALPRE
Date made public: 18 December 2018
Financial year end date: 31 December
Number of shares: 3,660,305
Predilife share price: 6,02 € au 02/07/2022 à 16:13